Summary of Langzi Co., Ltd. Conference Call Company Overview - **Company**: Langzi Co., Ltd. - **Industry**: Medical Aesthetics and Fashion Retail Key Financial Performance - **Net Profit**: For the first three quarters of 2025, the net profit attributable to shareholders reached 989 million yuan, a year-on-year increase of 366% [2][3] - **Non-recurring Net Profit**: Decreased by 4.1% year-on-year, indicating a need for improvement in profit quality [2][3] - **Operating Cash Flow**: Slight decline observed, reflecting potential operational challenges [2][3] Medical Aesthetics Business - **Revenue Contribution**: Medical aesthetics revenue exceeded 50% of total revenue for the first time, reaching 2.237 billion yuan, a 2.5% increase year-on-year [2][4] - **Gross Margin**: Improved to 55.6%, up 1.8 percentage points year-on-year [2][4] - **Net Profit Contribution**: Decreased by 33.5% year-on-year, indicating challenges in profitability [2][4] - **Revenue Breakdown**: - Milan Fabric Division: 1.159 billion yuan, up 2.2% - Financial Services Division: 393 million yuan, up 9.7% - Hancheng Division: 318 million yuan, up 16% - Wuhan Wuzhou: 146 million yuan, down 9% - Changsha Yamei: 132 million yuan, down 13% - Gao Doctor: 109 million yuan, down 11% [4] Women's Clothing Business - **Revenue**: Approximately 1.407 billion yuan, stable year-on-year [5] - **Gross Margin**: Maintained at around 64% [5] - **Net Profit Contribution**: Increased by 1% year-on-year [5] - **Online Sales Growth**: Significant growth of over 22%, accounting for more than 46% of total women's clothing revenue [5] - **Inventory**: Total inventory at the end of Q3 was approximately 769 million yuan, with a focus on preparing for Q4 [5] Yingdong Division Performance - **Revenue**: Approximately 674 million yuan, a slight decline of 1.6% year-on-year [7] - **Gross Margin**: Decreased by 4.2 percentage points to 61.4% [7][8] - **Net Profit**: Approximately 6.87 million yuan, down 33% [8] Trends in Medical Aesthetics - **Revenue Trends**: Despite a 6% decline in half-year revenue, Q3 showed slight growth of about 2% [9] - **Product Mix Changes**: - Regenerative materials accounted for 22% of revenue, up 5.1 percentage points - Hyaluronic acid decreased to 12.6%, down 1.9 percentage points [9] - **Light Medical Aesthetics**: Increased focus on light medical aesthetics projects, with significant growth in revenue [10] Strategic Considerations - **Pricing Strategy**: Emphasis on providing comprehensive solutions rather than relying solely on product pricing [12] - **Cost Management**: Efforts to reduce customer acquisition costs through channel optimization and content marketing [12] - **M&A Strategy**: Active pursuit of high-quality medical aesthetics targets through external fund acquisitions, with a focus on integration [14][17] Market Environment and Future Outlook - **Market Conditions**: Current market conditions have influenced M&A activities, with many small institutions being acquired for better growth opportunities [15][16] - **Investment Plans**: Positive outlook on future growth, especially in new regions, with ongoing monitoring of potential targets [17] Cost and Supplier Dynamics - **Material Costs**: Decreased by 1.4 percentage points year-on-year, benefiting from strong supplier relationships [19] - **Supplier Power**: Upstream suppliers maintain significant power, particularly in high-end products [20] This summary encapsulates the key points from the conference call, highlighting the financial performance, business segments, strategic initiatives, and market dynamics of Langzi Co., Ltd.

Financial Performance - In the first three quarters of 2025, the company achieved total revenue of approximately 4.328 billion yuan, a year-on-year increase of 0.89% [2] - Gross profit margin reached 59.35%, an increase of 1.77 percentage points compared to the same period last year [2] - Net profit attributable to shareholders was approximately 366.95 million yuan, a year-on-year increase of 0.5% [2] - Net cash flow from operating activities was approximately 359 million yuan, a year-on-year decrease of 1.87% [2] - Basic earnings per share were 2.2346 yuan, a year-on-year increase of 366.90% [2] - Total assets were approximately 8.617 billion yuan, a year-on-year increase of 5.67% [3] - Net assets attributable to shareholders were approximately 3.413 billion yuan, a year-on-year increase of 19.07% [3] Business Segment Performance - Medical beauty segment revenue was approximately 2.237 billion yuan, a year-on-year increase of 2.49% [3] - Women's clothing segment revenue was approximately 1.407 billion yuan, a year-on-year increase of 0.08% [3] - Infant and child segment revenue was approximately 674 million yuan, a year-on-year decrease of 1.58% [3] Investment Activities - The company generated investment income of approximately 970 million yuan from the disposal of part of its equity in Ruoyuchen [4] - The company acquired 67.50% of Chongqing Milan Baiyu Time Aesthetic Hospital for 92.475 million yuan, with a valuation dynamic price-earnings ratio of 13.38 times [4][5] - Performance commitments for Chongqing Time's net profit are set at no less than 9.29 million yuan, 9.89 million yuan, and 11.83 million yuan for 2025, 2026, and 2027 respectively [5] Online and Offline Sales Channels - Online sales for women's clothing reached approximately 652 million yuan, a year-on-year increase of 22.55% [9] - Online sales accounted for 46.80% of women's clothing revenue, an increase of 8.8 percentage points [9] - The company is integrating online and offline channels to enhance customer experience and increase repurchase rates [9] Inventory Management - As of September 30, 2025, the net value of women's clothing inventory was approximately 630 million yuan, a year-on-year increase of 13.84% [10] - Inventory less than one year old was approximately 522 million yuan, a year-on-year increase of 23.55% [10]

Core Viewpoint - Langzi Co., Ltd. has shown significant stock performance with a year-to-date increase of 25.81% and a notable rise of 372.50% in net profit for the first nine months of 2025 compared to the previous year [1][2]. Financial Performance - As of September 30, 2025, Langzi Co., Ltd. achieved a revenue of 4.328 billion yuan, reflecting a year-on-year growth of 3.58% [2]. - The company's net profit attributable to shareholders reached 989 million yuan, marking a substantial increase of 372.50% year-on-year [2]. Stock Market Activity - On November 3, 2025, Langzi's stock price rose by 2.03%, reaching 20.08 yuan per share, with a trading volume of 392 million yuan and a turnover rate of 7.84% [1]. - The total market capitalization of Langzi Co., Ltd. is approximately 8.884 billion yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.93% to 51,400, while the average circulating shares per person increased by 12.27% to 4,957 shares [2]. - The company has distributed a total of 1.4 billion yuan in dividends since its A-share listing, with 376 million yuan distributed in the last three years [3]. Business Segmentation - The main revenue sources for Langzi Co., Ltd. include non-surgical medical beauty services (41.59%), women's dresses (11.34%), and women's tops (11.22%) [1]. - The company operates in the textile and apparel industry, specifically in non-sports clothing, and is involved in various concept sectors such as C2M, private hospitals, medical beauty, cosmetics, and small-cap stocks [1].

Industry Overview - In 2025, social consumption and retail enterprises are slowly recovering, with segments like gold jewelry benefiting from high gold prices, while cosmetics and medical aesthetics face intense competition and the rise of domestic brands. Notably, "emotional consumption" remains a key indicator of market vitality [2][8]. Segment Analysis Gold Jewelry - The industry has undergone significant changes, with high gold prices and declining wedding demand affecting traditional brand competitiveness. The rise of emotional consumption and social media marketing has led to the emergence of new brands with differentiated products and consumer insights. Opportunities are seen in high-end Chinese gold and trendy gold segments [3][25]. Retail E-commerce - Offline retailers are transforming from selling "goods" to offering "services and experiences," leveraging their advantages to attract traffic back. Online cross-border e-commerce is expected to enter a demand improvement phase with the easing of interest rates, further enhanced by AI integration [3][19]. Cosmetics - Domestic brands are capitalizing on cultural roots and emotional value to increase market share. Innovations in product safety and emotional value are key, with opportunities in regional and technological narratives, sensitive skin anti-aging, and domestic color cosmetics [3][85]. Medical Aesthetics - High-end consumers show resilience, with a focus on differentiated products from upstream manufacturers and mergers and acquisitions among downstream medical institutions to drive growth [3][5]. Investment Recommendations - Gold Jewelry: Favor brands with differentiated product strength and consumer insights, recommending Chao Hong Ji, Lao Pu Gold, and Chow Tai Fook, with beneficiaries including Chow Sang Sang [3][52]. - Retail E-commerce: Support offline retailers adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket, Ai Ying Shi, Ji Hong Co., and Sai Wei Times [3][82]. - Cosmetics: Highlight domestic brands that meet emotional value and safety innovation, recommending Mao Ge Ping, Pechoin, Shangmei Co., Juzi Biological, Wanmei Biological, and Runben Co. [3][52]. - Medical Aesthetics: Focus on differentiated medical aesthetic product manufacturers and expanding chain medical institutions, recommending Ai Mei Ke and Ke Di-B, with beneficiaries including Mei Li Tian Yuan Medical Health [3][52].

Core Points - Langzi Co., Ltd. announced on October 31 that it has applied for a credit limit of RMB 50 million from CITIC Bank Beijing Branch to meet its daily operational and business development funding needs [2] - The company's controlling shareholder and actual controller, Mr. Shen Dongri, along with his spouse, Ms. Weng Jie, will provide guarantee collateral for the credit [2]

Market Overview - As of October 31, the Shanghai Composite Index closed at 3954.79 points, down 32.11 points, a decrease of 0.81% [1] - The Shenzhen Component Index closed at 13378.21 points, down 153.91 points, a decrease of 1.14% [1] - The ChiNext Index closed at 3187.53 points, down 75.49 points, a decrease of 2.31% [1] Stock Performance - A total of 63 A-shares had a turnover rate exceeding 20% on October 31, with Haike Xinyuan reaching a turnover rate of over 50% [1] - The top stocks by turnover rate included: - Haike Xinyuan (301292) with a closing price of 36.25 yuan and a turnover rate of 55.34%, increasing by 17.69% [1] - Chaoying Electronics (603175) with a turnover rate of 42.83%, decreasing by 9.99% [1] - Haixia Innovation (300300) with a turnover rate of 42.56%, increasing by 20.02% [1] - Other notable stocks included: - C Beite (688759) with a turnover rate of 42.39%, decreasing by 1.92% [1] - Marco Polo (001386) with a turnover rate of 40.99%, decreasing by 7.33% [1] Additional Notable Stocks - Other stocks with significant turnover rates included: - Daway Co. (002213) with a turnover rate of 40.46%, increasing by 3.89% [1] - Chuling Information (300250) with a turnover rate of 39.32%, increasing by 0.64% [1] - Huadong CNC (002248) with a turnover rate of 37.94%, increasing by 3.24% [1] - C Heyuan (688765) with a turnover rate of 37.86%, increasing by 4.79% [1] - The performance of other stocks varied, with some experiencing declines, such as: - Jianfa Zhixin (301584) with a turnover rate of 36.07%, decreasing by 8.09% [1] - Geer Software (603232) with a turnover rate of 33.38%, decreasing by 8.91% [1]

Core Insights - The apparel and home textile sector increased by 0.93% on October 31, with Aokang International leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Aokang International (603001) closed at 9.01, up 10.01% with a trading volume of 233,400 shares and a transaction value of 205 million yuan [1] - Other notable gainers included: - Jialinjie (002486) at 3.02, up 5.59% [1] - Kute Intelligent (300840) at 19.02, up 4.74% [1] - Bangjie Co. (002634) at 5.08, up 4.10% [1] - Conversely, Meibang Fashion (002269) saw a significant decline of 10.16%, closing at 2.21 with a trading volume of 3,501,900 shares and a transaction value of 780 million yuan [2] Capital Flow - The apparel and home textile sector experienced a net outflow of 101 million yuan from institutional investors and 137 million yuan from speculative funds, while retail investors contributed a net inflow of 239 million yuan [2] - Notable capital flows included: - Langzi Co. (002612) had a net inflow of 51.68 million yuan from institutional investors [3] - Jialinjie (002486) saw a net inflow of 32.02 million yuan from institutional investors [3] - Aokang International (603001) had a net inflow of 28.18 million yuan from institutional investors [3]

证券代码：002612 证券简称：朗姿股份 公告编号：2025-066 法定代表人：申东日 朗姿股份有限公司 关于接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司" 或"朗姿股份"）向中信银行股份有限公司北京分行（以下简称"中信银行"）申请 授信额度人民币 5,000 万元，公司控股股东、实际控制人申东日先生及其配偶翁 洁女士为公司提供保证担保。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司提供本次保 证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 二、被担保人基本情况 朗姿股份 注册资本：442,445,375 元人民币 成立日期：2006 年 11 月 09 日 注册地址：北京市顺义区马坡镇白马路 63 号 经营范围：一般项目：服装服饰零售；服饰研发；服饰制造；服装服饰批发； 服装、服饰检验、整理服务；服装辅料销售；互联网销售（除销售需要许可的商 品）；服装辅料制造；服装制造；针纺织品及原料销售；鞋帽批发； ...

Core Viewpoint - Langzi Co., Ltd. has shown a significant increase in stock price, reaching 19.94 CNY per share with a market capitalization of 8.822 billion CNY, indicating strong investor interest and trading activity [1]. Company Overview - Langzi Co., Ltd. was established on November 9, 2006, and went public on August 30, 2011. The company is based in Chaoyang District, Beijing, and specializes in the design, production, and sales of branded women's clothing [1]. - The main revenue composition of Langzi includes: non-surgical medical beauty (41.59%), women's skirts (11.34%), women's tops (11.22%), children's clothing (10.90%), women's outerwear (9.55%), surgical medical beauty (6.21%), children's products (4.70%), women's pants (3.31%), and others (1.18%) [1]. Shareholder Information - Among the top ten circulating shareholders of Langzi, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 24,300 shares in the third quarter, now holding 2.021 million shares, which accounts for 0.79% of the circulating shares [2]. - The Southern CSI 1000 ETF has a total scale of 76.63 billion CNY and has achieved a year-to-date return of 27.12%, ranking 2130 out of 4216 in its category [2]. Fund Management - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 6 years and 360 days. The total asset scale under management is 122.76 billion CNY, with the best fund return during the tenure being 182.39% and the worst being -15.93% [3].

Core Viewpoint - Langzi Co., Ltd. is a well-known enterprise in the domestic fashion consumption sector, with strong brand influence and resource reserves in the medical beauty industry [1] Group 1: Business Performance - In Q3 2025, Langzi achieved a revenue of 4.328 billion yuan, ranking 5th among 38 companies in the industry, with the top company, Hailan Home, generating 15.599 billion yuan [2] - The net profit for the same period was 1.019 billion yuan, ranking 3rd in the industry, with the top company, Youngor, reporting 2.334 billion yuan [2] - The main business composition includes non-surgical medical beauty at 1.16 billion yuan (41.59% of revenue) and women's clothing at 316 million yuan (11.34% of revenue) [2] Group 2: Financial Ratios - As of Q3 2025, Langzi's debt-to-asset ratio was 52.95%, down from 54.17% year-on-year, which is higher than the industry average of 38.41% [3] - The gross profit margin for the same period was 59.35%, up from 58.92% year-on-year, exceeding the industry average of 44.68% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 10.93% to 51,400, while the average number of circulating A-shares held per shareholder increased by 12.27% to 4,957.27 [5] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5] Group 4: Management Compensation - The chairman, Shen Dongri, received a salary of 899,600 yuan in 2024, a slight decrease from 900,000 yuan in 2023 [4] - The general manager, Shen Jinhua, also received a salary of 899,600 yuan in 2024, reflecting the same decrease [4] Group 5: Strategic Developments - The company has been actively expanding its medical beauty segment, acquiring Chongqing Milan Baiyu Time Aesthetic Hospital, and has established seven medical beauty acquisition funds with a total scale of 2.837 billion yuan [6] - The revenue from the light medical beauty chain brands "Jingfu Medical Beauty" and "Hancheng Medical Beauty" grew by 6.0% and 9.5%, respectively, in the first half of 2025 [6]